Data from preclinical experiments and a phase I study showed that GEN1046, another bsAb targeting 4-1BB and PD-L1, regresses tumor growth by increasing the proliferation of T cells and cytokine secretion, including IFN-γ, IL-10, and CXCL1072,73. Here, IFNG is linked to neoplasm.